Newsroom | 9639 results

Sorted by: Latest
Mental Health
-

Liven Challenges Toxic Cheerfulness This Holiday Season, Calling Attention to Emotional Overload

LAS VEGAS--(BUSINESS WIRE)--The holiday season is often framed as a time of joy and celebration. Yet for many, it brings emotional overload, increased pressure, and the expectation to appear cheerful. This winter, Liven, the company behind a self-discovery app, is challenging the cultural norm of toxic cheerfulness by encouraging honest conversations about stress, expectations, and the importance of self-reflection through its campaign. “The holidays often trigger accumulated emotions we’ve lea...
-

LivaNova to Present at J.P. Morgan Healthcare Conference in January

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w...
-

Haven of Hope Commits to Expanding Life-Saving Adolescent Eating Disorder Care in Tennessee

MEMPHIS, Tenn.--(BUSINESS WIRE)--Haven of Hope announced plans to open Tennessee’s first adolescent residential eating disorder treatment program in the Chattanooga area in 2026....
-

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY® (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. COBENFY is the first schizophrenia therapy with a novel mechanism of action approved in over 70 years [1], offering a fundamentally new approach to treating schizophrenia. By selectively activating M...
-

Toshiba & Partners Donate $114,000 to Help Veteran & Youth Causes

MITCHELL, S.D. & LAKE FOREST, Calif.--(BUSINESS WIRE)--Toshiba America Business Solutions, its reseller partners and US Bank raised $114,000 for the Sam Tronnes Memorial Foundation, LLC this season....
-

Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week

MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)--Newron will host investor and partnering meetings on January 12-14, 2026, coinciding with the 44th Annual J.P. Morgan Conference in San Francisco....
-

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares will cease trading on the NYSE American at market close...
-

Resumen: Syremis Therapeutics inicia su actividad con una financiación de 165 millones de dólares para desarrollar medicamentos de referencia para trastornos de la salud mental

Tel Aviv y Boston--(BUSINESS WIRE)--Syremis Therapeutics, una empresa biofarmacéutica en fase clínica dedicada al desarrollo de nuevos medicamentos con el objetivo de generar un impacto significativo en el tratamiento de los trastornos de la salud mental, ha anunciado hoy su lanzamiento respaldado por una financiación de 165 millones de dólares. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada...
-

Samenvatting: Syremis Therapeutics lanceert met $165 miljoen om de beste medicijnen te ontwikkelen voor psychische aandoeningen

Tel Aviv en Boston--(BUSINESS WIRE)--Syremis Therapeutics, een biofarmaceutisch bedrijf in de klinische fase dat nieuwe medicijnen ontwikkelt om een grote impact te hebben op de behandeling van psychische aandoeningen, heeft vandaag de lancering aangekondigd met een financiering van $ 165 miljoen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is....
-

Riassunto: Nasce Syremis Therapeutics: un investimento da 165 milioni di dollari per lo sviluppo di farmaci best in class mirati al trattamento della salute mentale

Tel Aviv e Boston--(BUSINESS WIRE)--Syremis Therapeutics, azienda biofarmaceutica di fase clinica impegnata nello sviluppo di nuovi farmaci mirati a un forte impatto sul trattamento della salute mentale, oggi ha annunciato di avere iniziato le attività a seguito di un finanziamento da 165 milioni di dollari USA. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono...